Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Fig. 5

Targeting CD73 improves cytolytic activity of piggyBac-NKG2D.CAR-NK cells. CD73 expression levels on (a) GBM43, (b) GBM10, (c) A549, and (d) PC3 cell lines, respectively. Lytic activity of piggyBac-NKG2D.CAR-NK-92 cells against (e) GBM43, (f) GBM10, (g) A549 or (h) PC3 cells, in the presence of anti-CD73 antibody and adenosine deaminase inhibitor (ADAi) EHNA (30 μM), respectively. Data are presented as the mean ± SEM (n = 4). *P < 0.05, **P < 0.01

Back to article page